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Objective: Glucagon-like peptide-1 induces glucose-dependent insulin secretion and, in rodents, 
increases proliferation and survival of pancreatic beta cells. To investigate the effects on human 
beta cells, we used immunodeficient mice transplanted with human islets. The goal was to 
determine whether lixisenatide, a glucagon-like peptide-1 receptor agonist, improves human 
islet function and survival in vivo.
Methods: Five independent transplant studies were conducted with human islets from five 
individual donors. Diabetic human islet-engrafted immunodeficient mice were treated with 
lixisenatide (50, 150, and 500 µg/kg) or vehicle. Islet function was determined by blood glucose, 
plasma human insulin/C-peptide, and glucose tolerance tests. Grafts were analyzed for total 
beta- and alpha-cell number, percent proliferation, and levels of apoptosis.
Results: Diabetic mice transplanted with marginal human islet mass and treated with lixisenatide 
were restored to euglycemia more rapidly than vehicle-treated mice. Glucose tolerance tests, 
human plasma insulin, and glucose-stimulation indices of lixisenatide-treated mice were signifi-
cantly improved compared to vehicle-treated mice. The percentages of proliferating or apoptotic 
beta cells at graft recovery were not different between lixisenatide-treated and vehicle-treated 
mice. Nevertheless, in one experiment we found a significant twofold to threefold increase in 
human beta-cell numbers in lixisenatide-treated compared to vehicle-treated mice.
Conclusion: Diabetic human islet-engrafted immunodeficient mice treated with lixisenatide 
show improved restoration of normoglycemia, human plasma insulin, and glucose tolerance 
compared to vehicle-treated mice engrafted with the same donor islets. Because the prolifera-
tive capacity of human beta cells is limited, improved beta-cell survival coupled with enhanced 
beta-cell function following lixisenatide treatment may provide the greatest benefit for diabetic 
patients with reduced functional islet mass.
Keywords: GLP-1 receptor agonist, lixisenatide, human islet transplant, beta cells, glucose 
tolerance tests, plasma insulin
Introduction
Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists have been reported to 
improve beta-cell function and viability.1–3 At the beta-cell level, GLP-1 and its receptor 
agonists were found to induce beta-cell proliferation and decrease beta-cell apoptosis 
in rodents and in vitro.3–6 In vivo, GLP-1 receptor agonists preserve beta-cell mass in 
multiple animal models of diabetes,3,7–9 although an effect on beta-cell mass/number has 
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not yet been demonstrated in humans. In clinical trials with 
type 2 diabetes (T2D) patients, GLP-1 receptor agonists low-
ered both fasting and postprandial glucose concentrations;10,11 
GLP-1 receptor agonists also potentiate glucose-dependent 
insulin secretion, and thus have a low propensity to cause 
hypoglycemia.12 However, in patients with long-standing type 
1 diabetes, C-peptide secretion was not increased, although 
insulin sensitivity improved.13,14
Lixisenatide is a recently developed GLP-1 receptor 
agonist with potent binding affinity and extended biological 
activity.15–18 In patients with T2D, once-daily administration 
of lixisenatide improved glycemic control by decreasing 
both postprandial and fasting glucose levels; moreover, these 
effects were both immediate and sustained.19–22 In addition 
to increased insulin secretion in response to meal-related or 
glucose stimulation, a reduction in endogenous glucose pro-
duction and slowing of gastric emptying also contribute to the 
reduction in postprandial blood glucose levels observed with 
lixisenatide and other GLP-1 receptor agonists.22–25 In vitro 
studies with an INS-1 rat pancreatic beta-cell line indicates 
that GLP-1 and its receptor agonists, including lixisenatide, 
protect against lipid- and cytokine-induced apoptosis.26 Even 
so, it is not possible to directly assess beta-cell apoptosis in 
patients due to the inaccessibility of pancreatic islets, and 
clinical studies are difficult to control due to the variability 
between patients in regards to age, sex, diet, and other life-
style factors.
A useful method to interrogate human islet function 
in vivo is to transplant human islets into diabetic immu-
nodeficient nonobese diabetic–severe combined immu-
nodeficiency (NOD–scid) IL-2 receptor common gamma 
chain (IL-2rgnull) (NSG) mice.27 Many diabetes-inducing 
chemicals, such as streptozotocin, may cause damage to 
other organs. Also, the chemical-induced destruction of 
endogenous beta cells is not always complete, rendering 
problematic the interpretation of long-term transplantation 
studies with exogenous islets. To circumvent these issues, 
we utilized a strain of transgenic NSG mice that uses the 
rat insulin promoter (RIP) to drive human diphtheria toxin 
receptor (DTR) expression in the animal’s beta cells. When 
treated with low doses of diphtheria toxin, the NSG RIP-
DTR mouse model allows complete and specific ablation of 
mouse pancreatic beta cells and thereby avoids broadly toxic 
agents such as streptozotocin. The goal of this study was to 
investigate the efficacy of lixisenatide to promote human 
beta-cell function, proliferation, and survival using diabetic 
NSG RIP-DTR mice engrafted with marginal amounts of 
human pancreatic islets.
Methods
Mice and diabetes induction
NOD.Cg-PrkdcscidIl2rgtm1Wjl Tg(Ins2-HBEGF)6832 
Ugfm/Sz mice, referred to as NSG RIP-DTR mice, were 
developed at the Jackson Laboratory, Bar Harbor, ME, USA, 
by backcrossing the RIP-DTR transgene from a B6;CBA-RIP-
DTR stock kindly provided by Pedro Herrera. The original 
B6;CBA Tg(Ins2-HBEGF)6832 Ugfm/Sz mice were made 
by injecting the construct into B6;CBA eggs. The transgene 
was backcrossed using a marker-assisted speed congenic 
method to the NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (abbreviated 
as NOD–scid IL-2rgnull or NSG) strain background. These 
NSG RIP-DTR mice express the human DTR driven by a 
RIP. The RIP-DTR transgene was then fixed to homozygosity. 
All mice were housed in a specific pathogen-free facility 
and maintained in accordance with the Institutional Animal 
Care and Use Committee of the University of Massachusetts 
Medical School.28
To induce diabetes, male NSG RIP-DTR mice 
(8–12 weeks old) were injected intraperitoneally (ip) with 
20 ng diphtheria toxin (List Biological Laboratories, Camp-
bell, CA, USA) diluted in sterile phosphate-buffered saline 
(PBS). Blood glucose was monitored with an Accu-chek 
Aviva Plus glucometer (Hoffman-La Roche Ltd, Basel, 
Switzerland) to confirm diabetes (blood glucose .300 
mg/dL on 2 consecutive days). Diabetic mice that were not 
transplanted with human islets within 1 week were given 
insulin implants (LinShin Canada Inc., Scarborough, ON, 
Canada) to prevent metabolic decompensation until human 
islets were available.
Pharmacokinetic analyses
An initial pharmacokinetic study with unengrafted, 
euglycemic NSG mice was performed to determine the 
plasma levels of lixisenatide over a 24-hour period fol-
lowing treatment. All mice were injected subcutaneously 
(sc) with vehicle alone or with 50 µg/kg, 150 µg/kg, or 
500 µg/kg lixisenatide (provided by Sanof i-Aventis, 
Frankfurt,  Germany). Blood was collected in potassium 
ethylenediaminetetraacetic acid (K-EDTA) tubes at 0, 5, 
15, 30, 60, and 120 minutes and 4, 8, and 24 hours from 
three mice/group at each time point; plasma was stored at 
−80°C. High-performance liquid chromatography analy-
sis of  lixisenatide levels in blood plasma was performed 
by Sanof i-Aventis. Based on these time-course data 
( Figure S1), the mice in the transplant studies were treated 
twice daily with the same concentrations of lixisenatide as 
in the pharmacokinetic study.
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human islet transplantation and 
lixisenatide treatment
Human islets were obtained from the Integrated Islet Dis-
tribution Program under protocols approved by the Insti-
tutional Review Board of the University of Massachusetts 
Medical School. Islets were transplanted into the subrenal 
capsular space as previously described;29 insulin implants 
were removed upon transplant. Five independent transplant 
studies were performed, each with human islets from a single 
donor. One day post-transplant, the mice were randomized 
into four groups, with five to seven mice in each group. The 
mice were injected sc twice daily with lixisenatide (50, 150, 
or 500 µg/kg/injection) or vehicle until graft removal at 
∼4 weeks post-transplant.
glucose tolerance test, plasma insulin/c-
peptide, and glucose stimulation index
For the glucose tolerance test (GTT), mice were fasted for 
5–6 hours, and blood glucose was measured following ip 
injection of glucose (2.0 g/kg body weight). To measure 
plasma levels of human insulin and C-peptide, heparinized 
blood from transplanted mice was collected with protease 
inhibitor (aprotinin; Sigma-Aldrich Co, St Louis, MO, 
USA). Non-fasting blood samples were collected just 
prior to drug/vehicle treatment. On alternate weeks, the 
mice were fasted for 5–6 hours prior to glucose injection 
(2 g/kg, ip); in the Donor 1 study, arginine (1 g/kg, ip) 
was given in addition to glucose. Blood was collected at 
0 (fasted) and 15 minutes (stimulated) post-injection; the 
glucose stimulation index was determined as the ratio of 
plasma insulin at 15 and 0 minutes. All plasma was stored 
at −80°C until analyzed by human-specific enzyme-linked 
immunosorbent assay (ELISA) (ALPCO Diagnostics, 
Salem, NH, USA).
Bromodeoxyuridine treatment, 
immunofluorescence staining,  
and TUnel assay
Human islet-engrafted mice were provided drinking water 
containing 0.8 mg/mL of bromodeoxyuridine (BrdU) ad 
libitum for 7 days prior to nephrectomy of the graft-bearing 
kidney. Euglycemic mice at the time of nephrectomy were 
followed for reversion to hyperglycemia for confirmation 
of human islet graft function. Islet graft-bearing kidneys 
were fixed in 10% neutral-buffered formalin. Paraffin-
embedded sections were stained with guinea pig anti- insulin 
(Dako, Carpinteria, CA, USA), mouse anti-glucagon 
(Abcam, Cambridge, England), and rat anti-BrdU (Accu-
rate Chemical, Westbury, NJ, USA); secondary Alexa Fluor 
antibodies (Alexa Fluor 647, 594, 488) were from Life 
Technologies (Carlsbad, CA, USA), and 4′,6-diamidino-2-
phenylindole (DAPI) was from Sigma-Aldrich Co. Insulin+, 
insulin+BrdU+, glucagon+, and glucagon+BrdU+ cells were 
visualized by fluorescence microscopy (Nikon Eclipse Ti 
series; Nikon Corporation, Tokyo, Japan). Terminal deoxy-
nucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) assay was performed as per manufacturer’s instruc-
tions (Hoffman-La Roche Ltd). All counts were performed 
with Nikon NIS Elements software.
Total beta- and alpha-cell counts in human 
islet grafts
To determine total beta- and alpha-cell numbers in the islet 
grafts, 5 µm serial sections were cut through the entire graft 
and immunostained for insulin and glucagon. Beginning at 
the outer edge of the graft, images of the entire section were 
taken and stitched with a Nikon Eclipse Ti series microscope 
with motorized x–y stage. Subsequent serial sections were 
counted at 20 µm intervals to avoid duplicate counting of 
the same cells; all counts were performed with Nikon NIS 
Elements software.
Statistical analyses
Time-course data were analyzed by two-way analysis of 
variance (ANOVA) with Tukey’s or Holm–Sidak’s multiple 
comparisons test; insulin levels, cell counts, proliferation, 
and TUNEL data were analyzed by one-way ANOVA 
with Bonferroni’s or Tukey’s multiple comparisons test 
when comparing the four groups. Percent diabetes survival 
(Kaplan–Meier) was analyzed by Mantel–Cox log rank test. 
All statistical analyses were performed with GraphPad Prism 
(San Diego, CA, USA); P-values ,0.05 were considered 
significant.
Results
lixisenatide treatment accelerates 
restoration of normoglycemia in diabetic 
mice engrafted with human islets
Diabetic NSG RIP-DTR mice were engrafted with human 
islets from a single donor, randomized into four groups, and 
treated with vehicle (control) and lixisenatide at 50 µg/kg 
(low dose), 150 µg/kg (medium dose), and 500 µg/kg (high 
dose). A total of five independent studies were done with 
human islets from five donors; none of the donors were 
diagnosed as diabetic. The demographic characteristics of 
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the islet donors and the numbers of islet equivalents (IEQs) 
transplanted into each mouse for each study are shown in 
Table 1.
Blood glucose and body weight measurements of the 
mice were taken prior to islet transplant and then twice 
weekly following transplantation (Figure 1A and B). In 
four of the five transplant studies, mice treated with lixisen-
atide exhibited significant improvement in blood glucose 
control more rapidly than mice receiving vehicle alone 
(Figure 1A). In the Donor 2 study, only the high-dose lix-
isenatide mice showed significant improvement in blood 
glucose (at 9 and 13 days post-transplant). The mice in all 
other groups remained hyperglycemic; consequently, all 
mice engrafted with Donor 2 islets were euthanized without 
further analysis.
A combined survival curve analysis for transplant studies 
with islets from Donors 1, 3, 4, and 5 showed that lixisen-
atide treatment improved recovery from diabetes with high 
statistical power (Figure 2). The median time for the mice 
to become diabetes free was 12 days for the vehicle control 
group, and 5, 3, and 4 days for low-, medium-, and high-dose 
lixisenatide-treated groups, respectively. On surgical exci-
sion of the graft-bearing kidney, all mice became acutely 
hyperglycemic (blood glucose .500 mg/dL, Figure 1A), 
thus verifying that the human islet graft was responsible for 
maintaining blood glucose levels.
lixisenatide treatment is associated  
with improved body weight maintenance
Mouse body weights were measured during each transplant 
study. In the Donor 1 study, all mice lost significant weight 
between the time of transplant and nephrectomy, except 
the medium-dose group (Figure 1B), which also showed 
the best blood glucose control. In transplant studies with 
islets from Donors 2 and 5, mice in the control group lost 
a small, but significant, amount of weight. This weight 
loss was not unexpected because these control mice were 
hyperglycemic throughout the trial. However, it is interest-
ing to note that none of the lixisenatide-treated mice in the 
Donor 2 and 5 studies showed significant weight loss, even 
though some of the mice in the lower dose groups were 
also hyperglycemic. In transplant studies with islets from 
Donors 3 and 4, in which normoglycemia was eventually 
restored in all mice, there was no significant change in body 
weight of the mice in either the control or lixisenatide-treated 
groups.
glucose-stimulated human insulin 
secretion is increased in islet-engrafted 
mice treated with lixisenatide
At 2 weeks post-transplant, the fasting levels of human insu-
lin showed no significant differences between control and any 
of the lixisenatide-treatment groups (Figure 3A). However, 
glucose-stimulated levels of human insulin were signifi-
cantly increased with medium-dose lixisenatide treatment 
in Donors 1 and 4 transplant studies (Figure 3B). Of note, 
the stimulation index (ratio of stimulated to fasting human 
insulin) was significantly increased compared to controls in 
the medium-dose group for Donor 1, and both medium- and 
high-dose groups for Donors 3 and 4 transplants (Figure 3C). 
Mice in the Donor 2 and 5 transplant studies were excluded 
because the controls (as well as some of the treated mice) 
were hyperglycemic.
lixisenatide treatment improves gTTs  
in human islet-engrafted mice
Consistent with the increased human insulin levels in 
lixisenatide-treated mice in response to glucose, lixisenatide 
treatment also significantly improved responses in GTTs in 
both the Donor 3 and 4 studies at 4 weeks post-transplant 
(Figure 4). Although mice in the Donor 4 study received 
uninterrupted drug treatment until the GTT, mice in the 
Donor 3 study continued to exhibit significantly improved 
glucose tolerance, even though lixisenatide treatment 
had been discontinued for 4 days prior to the GTT. In the 
Donor 3 transplant study, the mice treated with lixisenatide 
showed significant differences from controls in the medium-
dose (P,0.01) and high-dose (P,0.05) groups, whereas 
in the Donor 4 transplant study, the low-dose lixisenatide 
group showed significant differences from the control group 
(P,0.05).
Table 1 Demographic characteristics of human islet donors
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
age, years 30 53 43 51 61
Sex (M/F) M F nr M F
ethnicity hispanic/ 
latino
hispanic/ 
latino
nr hispanic/ 
latino
nr
Body  
weight, kg
95 105 nr 86 nr
BMi, kg/m2 30.9 42.7 34.7 28.9 22.2
Time  
in culture*
1 day,  
0 hour
3 days,  
12 hours
1 day,  
3 hours
2 days,  
10 hours
nr
Transplanted 
ieQs/mouse
2,500 2,500 3,000 3,000 3,000
Note: *refers to the amount of time for which the human islets were cultured 
following isolation until shipment to our laboratory.
Abbreviations: BMi, body mass index; F, female; ieQs, islet equivalents; M, male; 
nr, not recorded.
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Figure 1 Blood glucose and body weights of control and lixisenatide-treated mice engrafted with human islets.
Notes: Diabetic NSG RIP-DTR mice were transplanted with human islets from five individual donors and injected sc twice daily with lixisenatide or vehicle control; n=5–6 
per treatment group, mean ± SeM. *P,0.05, **P,0.01, and ***P,0.001. (A) Blood glucose levels of the mice were monitored on the days indicated. Donor 1, **medium 
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Abbreviations: nSg RIP-DTR, nonobese diabetic–severe combined immunodeficiency (NOD–scid) il-2 receptor common gamma chain (IL-2rgnull) rat insulin promoter-
diphtheria toxin receptor; SeM, standard error of mean; sc, subcutaneously.
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apoptosis and proliferation analyses of  
human islet grafts recovered from control 
and lixisenatide-treated mice
Treatment with GLP-1 receptor agonists has been reported 
to protect rodent pancreatic beta cells from apoptosis.1 To 
determine whether lixisenatide treatment modulates human 
beta-cell apoptosis, the islet grafts were recovered on days 29, 
32, and 21 (for Donor 3, 4, and 5 studies, respectively) and 
examined by TUNEL staining (Figure 5). We found no signifi-
cant differences in beta-cell apoptosis between the control and 
lixisenatide-treated groups at the time points examined (at 
the end of each islet transplant study). In addition, although 
there was a variability between donor islets, the average 
percent beta-cell apoptosis observed at the end of each study 
was very low (,1%).
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Figure 2 lixisenatide treatment improves recovery from hyperglycemia in human 
islet-engrafted mice.
Notes: Diabetic nSg riP-DTr mice were transplanted with human islets and treated 
with lixisenatide or vehicle control. Mice with blood glucose values .300 mg/dl were 
considered hyperglycemic. Data shown are pooled from islet transplants of Donors 1, 3, 
4, and 5; n=23–25 per treatment group. *P,0.05, ***P,0.001, ****P,0.0001.
Abbreviation: nSg RIP-DTR, nonobese diabetic–severe combined immunodeficiency 
(nOD–scid) il-2 receptor common gamma chain (IL-2rgnull) rat insulin promoter-
diphtheria toxin receptor.
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Figure 3 Fasting and glucose-stimulated human insulin levels and stimulation indices in control and lixisenatide-treated mice engrafted with human islets.
Notes: Blood was collected at fasting and 15 minutes after ip glucose injection; plasma levels of (A) fasting human insulin and (B) glucose-stimulated human insulin are shown. 
(C) Stimulation indices (glucose-stimulated insulin/fasting insulin) from vehicle control and lixisenatide-treated mice are shown; n=4 or 5 per group, mean ± SeM.
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Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
393
lixisenatide improves human islet grafts
To determine whether lixisenatide treatment induced 
human beta (or alpha)-cell proliferation, the mice were sup-
plied with BrdU in their drinking water for 1 week prior to 
recovery of the graft-bearing islets. The percentages of BrdU+ 
beta cells (Figure 6A) and BrdU+ alpha cells (Figure 6B) for 
each human islet graft are shown for control and lixisenatide-
treatment groups from Donor 3, 4, and 5 transplant studies 
combined. Consistent with previous reports,30–32 most islet 
grafts had very low levels of proliferating human beta cells, 
but neither beta- nor alpha-cell proliferation was significantly 
affected by lixisenatide treatment (as measured by BrdU 
incorporation during the last 7 days of each islet transplant 
study).
Quantitation of total beta and alpha cells 
in human islet grafts recovered from 
control and lixisenatide-treated mice
Our proliferation and apoptosis analyses reflect lixisenatide 
effects on the human islet grafts only as a “snapshot” at late 
stages of engraftment. Therefore, to better interrogate the 
effect of lixisenatide on human beta-cell survival throughout 
the ∼30-day treatment period, we counted total beta- and 
alpha-cell numbers within the recovered islet grafts. We 
observed considerable donor-to-donor variability with regard 
to the numbers of beta (Figure 7A) and alpha (Figure 7B) 
cells in the recovered islet grafts, even though the same 
numbers of IEQs were transplanted in each of the three 
studies examined.
In the Donor 5 transplant study, medium- and high-dose 
lixisenatide-treated mice displayed significantly greater beta-
cell numbers within the graft compared to control mice. In 
this study, an average of ∼2,000 beta cells was detected in the 
islet grafts of control mice compared to an average of ∼12,500 
and ∼4,500 beta cells in the control groups of Donor 3 and 
4 studies, respectively. Interestingly, Donor 5 control mice 
remained hyperglycemic throughout the study, whereas 
normoglycemia was restored in control group mice in the 
Donor 3 and 4 studies. The beta (and alpha)-cell counts in the 
low-dose lixisenatide-treated group from the Donor 5 study 
were approximately twofold higher than the control group, 
250
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even though the blood glucose of these mice remained 
elevated (∼400 mg/dL, Figure 1A). The blood glucose values 
in the medium- and high-dose groups were significantly lower 
than the control group, and these mice had approximately 
threefold higher numbers of beta (and alpha) cells. In sup-
port of this, the islet grafts from three vehicle control mice 
appear noticeably smaller than from lixisenatide-treated mice 
(Figure 8), consistent with the significantly lower beta- and 
alpha-cell counts in the control group.
Discussion
In this study, we demonstrated that lixisenatide treatment 
significantly improved human beta-cell function and survival 
in diabetic NSG RIP-DTR mice engrafted with human islets. 
The human islets were derived from both male and female 
islet donors, aged 30–61 years, with body mass index (BMI) 
from 22.2 to 42.7 kg/m2; none was diagnosed as having 
diabetes. Five independent islet transplant studies were 
conducted, and mice were treated with three different doses 
of lixisenatide (50, 150, and 500 µg/kg) and vehicle control. 
A significantly accelerated recovery from diabetes was 
observed in lixisenatide-treated mice compared to controls, 
with the median time to a diabetes-free condition of 5, 3, and 
4 days for low-, medium-, and high-dose lixisenatide groups, 
respectively, compared to controls at 12 days. The numbers 
of human islets transplanted were 2,500 IEQs in Donor 1 and 
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2 studies, and 3,000 IEQs in studies with Donors 3, 4, and 5. 
Although human islets from nondiabetic donors can comprise 
as few as 28% or as many as 75% beta cells,33 in our experi-
ence, ∼3,000 human IEQs is typically sufficient to restore 
normoglycemia in the NSG RIP-DTR model.
Plasma levels of human insulin and C-peptide in fed or 
fasted islet-engrafted mice were variable or not significantly 
different between the control and lixisenatide-treatment 
groups. In contrast, mice treated with medium- and high-dose 
lixisenatide (compared to control) had significantly increased 
glucose-stimulated plasma levels of human insulin and glucose-
stimulation indices for each of the three donors that were ana-
lyzed. This is consistent with human studies in T2D patients and 
nondiabetic subjects, in whom lixisenatide stimulated insulin 
secretion when blood glucose levels were increased, but not at 
normoglycemia.34 In support of this, GTTs were significantly 
improved in mice treated with lixisenatide compared to control 
mice engrafted with the same donor islets. Similarly, in a study 
with T2D patients insufficiently controlled on metformin, lix-
isenatide treatment provided a significantly greater reduction in 
postprandial plasma glucose than in placebo control.35
To measure the proliferation of human beta and alpha cells 
in the islet grafts, control and lixisenatide-treated mice were 
given BrdU in their drinking water 7 days before removal 
of the graft-bearing kidney. No significant differences were 
seen between lixisenatide treatment and control groups, 
although individual islet grafts derived from Donors 4 and 
5 tended to have more BrdU+ cells in control mice  compared 
to lixisenatide-treated animals engrafted with the same islets. 
Of note, control mice in the Donor 4 and 5 transplant stud-
ies had higher blood glucose levels than lixisenatide-treated 
mice, and we and others have reported that even mild hyper-
glycemia induces human beta-cell proliferation in human 
islet-engrafted mice.31,32 Nonetheless, beta cells from humans 
have a very low proliferation rate compared to rodents, and 
hyperglycemia induction results in only a ∼0.5% proliferative 
rate in human beta cells.30–32
GLP-1 and its receptor agonists have been reported to 
inhibit beta-cell apoptosis in short-term culture of insuli-
noma cells and freshly isolated human and rodent islets.8,26,36 
At recovery of the human islet grafts ∼4 weeks post-transplant, 
we observed no significant difference between lixisenatide-
treated and control groups in beta-cell apoptosis (as measured 
by TUNEL staining). However, it is possible that lixisenatide 
may have had an anti-apoptotic effect on the islet grafts at 
earlier stages in the post-transplant period. Indeed, it has been 
estimated that up to 70% of islet mass may be lost in the early 
post-transplant period, even in immunodeficient or syngeneic 
transplant models.37,38 Thus, it is likely that lixisenatide may 
have modulated beta-cell survival at earlier post-transplant 
time periods. In support of this, GLP-1 receptor agonist 
treatment of diabetic mice engrafted with syngeneic islets 
reversed the loss of both the number and mass of islets grafts 
at 1 and 3 days post-transplant.39 With longer GLP-1 receptor 
agonist treatment (2–3 weeks), both Ins2Akita (Akita) and Leprdb 
mice had increased islet mass and elevated pancreatic insulin 
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content compared with controls.7,8 Similarly, we found that 
lixisenatide treatment dramatically improved total beta- and 
alpha-cell numbers in human islet grafts from Donor 5.
In the Donor 5 transplant study, the human islets failed to 
lower blood glucose levels in the control group, and mice in 
the low-dose lixisenatide group also remained hyperglycemic. 
Remarkably, the insulin+ (beta) and glucagon+ (alpha) cell 
counts in the islet grafts of mice treated with low-dose lixisen-
atide were twofold greater than in the control group, and mice 
treated with medium- and high-dose lixisenatide had threefold 
greater numbers of alpha and beta cells. Because the low rate of 
human beta-cell proliferation cannot account for these differ-
ences in beta-cell numbers, these data are consistent regarding 
the role of lixisenatide to preserve human beta-cell survival.
It is possible that lixisenatide’s effect to maintain beta-
cell viability may be secondary to its ability to increase 
insulin secretion and lower blood glucose, thus preventing 
glucotoxicity. However, in Akita mice, the protective effect 
of GLP-1 receptor agonist on pancreatic islet mass was found 
to be independent of lowered blood glucose levels.7 Similarly, 
in our Donor 5 study, the low-dose lixisenatide group showed 
a twofold increase in beta-cell number compared to the 
control group, even though mice in this group remained 
hyperglycemic throughout the study. These data suggest that 
lixisenatide may have additional islet-protective effects on 
human beta cells, such as that previously reported in rodent 
diabetes models, in which GLP-1 receptor agonists acted to 
reduce beta-cell endoplasmic reticulum stress.3,7–9 Taken 
together, our data are consistent with a role for lixisenatide 
to preserve human beta-cell function and survival in vivo, in 
particular when numbers of functional beta cells are limiting, 
as would be found in individuals with T2D.
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Figure S1 Pharmacokinetic analysis of control and lixisenatide treatments.
Notes: nSg mice were given a single sc injection with vehicle control or three different doses of lixisenatide; plasma levels of lixisenatide were measured at the time points 
indicated; n=3 mice per group at each time point (n=96 mice total + 3 untreated mice at time 0). The data from one low dose mouse at the 24-hour time point were deemed 
a technical failure and removed from analysis.
Abbreviations: nSg, nonobese diabetic–severe combined immunodeficiency (NOD–scid) il-2 receptor common gamma chain (IL-2rgnull); sc, subcutaneously; conc, 
concentration.
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